Proteomic Based Drug Discovery Summit 2025

Determine Optimum Application of Proteomics to Accelerate Screening of Novel Targets, Unravel the Mode of Action, & Identify Biomarkers to Progress Small Molecule Drug Discovery & Translation into Clinic

Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year, Sanofi has dedicated $700M to Belharra Therapeutics to develop a proteomics platform and Galapagos has partnered with Bridgene Bio to combine chemoproteomics with computational tools.

This is the time to harness the power of proteomics to accelerate your drug development process and de-risk your pipeline.
The Inaugural Proteomics-Based Drug Discovery Summit comes to Boston as the first industry dedicated event to help solve bottlenecks across your drug development chain including hit screening, target validation, hit to lead progression and in vivo translation to leverage the power of the proteome and drug the “undruggable”.

In 2025, make sure you join experts where you will hear exclusive data revealed, towards supercharging your experiments for screening compound libraries, unravelling the mechanism of action, deconvoluting protein-protein interactions and determining drug potency to gear your proteomics platforms for faster development of more effective drugs to change patient lives.

Location: Boston, MA

Event Program: https://ter.li/oabwyv

Secure Your Pass: https://ter.li/oabwyvt

5 Reasons You Can’t Miss the World’s First Industry Dedicated Proteomics Summit:

Automate and miniaturize your sample preparation to develop high throughput mass spectrometry workflows without losing sensitivity with Plexium, Sanofi & Monte Rosa Therapeutics
Translate your small molecule drugs into the clinic with insights on mechanism of action, protein-protein interactions and protein networks from Covant Therapeutics, Pfizer & Rezo Therapeutics
Advance your screening toolkits to identify more “ligandable residues” for reliable drug discovery with Novartis, Vicinitas Therapeutics & Scorpion Therapeutics
Discover the bleeding edge of covalent drugs, molecular glues and degraders with next-generation platforms by Monte Rosa Therapeutics, BridGene Biosciences & Hyku Biosciences
Uncover selectivity profiles, target engagement, post-translational modifications and structural insights using the latest assays developed by Bayer, Biogen & Relay Therapeutics

Download the Agenda Here: https://ter.li/oabwyv

Register Your Spot Online: https://ter.li/oabwyvt